ADAlexey V. Dvornikov

Alexey V. Dvornikov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexey V. Dvornikov has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Myosin‐binding protein C slows cardiac myofibril relaxation kinetics

    by Alexey V. Dvornikov, Samantha P. Harris

    Mutations in cardiac myosin binding protein C (cMyBP‐C) are a leading cause of hypertrophic cardiomyopathy (HCM). Patients with HCM often have reduced cMyBP‐C expression, reduced protein phosphorylation, and diastolic dysfunction. Relaxation of a single myofibril in response to a sudden drop in activator calcium is biphasic, consisting of a slow isometric phase (kREL,slow) followed by a fast exponential phase (kREL,fast), considered to reflect cross‐bridge‐dependent and ‐independent processes, respectively. Here, we determined the effects of cMyBP‐C on myofibril activation and relaxation kinetics by deleting the C0‐C7 fragment of cMyBP‐C and replacing it using our ‘cut‐and‐paste’ method. Results show that acute loss of C0‐C7 desensitized myofilaments to Ca2+ and sped both phases of relaxation. Ligation of recombinant wild‐type C0‐C7 returned relaxation rates back to baseline, whereas ligation of phosphorylated cMyBP‐C left the fast relaxation phase accelerated and increased the rate of activation in response to Ca2+ (kACT). Mavacamten (Mava), an inhibitor of myosin, accelerated both phases of relaxation independently of the presence or absence of cMyBP‐C. Finally, we found that a point mutation in the M‐domain of cMyBP‐C (L348P) slowed both phases of relaxation. Taken together, we report that cMyBP‐C slows both phases of relaxation, suggesting that it affects relaxation via cross‐bridge‐dependent and ‐independent mechanisms. image Key points: Mutations in MYBPC3, the gene encoding cardiac myosin‐binding protein C, (cMyBP‐C) occur in ∼20%–25% of patients with hypertrophic cardiomyopathy. The majority of these mutations lead to reduced cMyBP‐C protein expression in sarcomeres (haploinsufficiency). Here we investigated effects of acute loss of cMyBP‐C on relaxation kinetics in mouse cardiac myofibrils using our ‘cut and paste’ approach. Results showed that cMyBP‐C slows both phases of myofibril relaxation. Phosphorylation of cMyBP‐C accelerated the fast phase of relaxation, whereas a point mutation (L348P) that increases the affinity of cMyBP‐C for actin, significantly slowed both phases of relaxation. Mavacamten, a myosin inhibitor, accelerated both phases of relaxation independently of cMyBP‐C. Overall, we interpret our results in terms of dual cross‐bridge‐dependent and cross‐bridge‐independent mechanisms of action of cMyBP‐C on cardiac relaxation.


  • Open Access

    Fluorescence lifetime-based assay reports structural changes in cardiac muscle mediated by effectors of contractile regulation

    by Alexey V. Dvornikov, Thomas A. Bunch, Victoria C. Lepak, Brett A. Colson

    Cardiac muscle contraction is regulated by Ca2+-induced structural changes of the thin filaments to permit myosin cross-bridge cycling driven by ATP hydrolysis in the sarcomere. In congestive heart failure, contraction is weakened, and thus targeting the contractile proteins of the sarcomere is a promising approach to therapy. However, development of novel therapeutic interventions has been challenging due to a lack of precise discovery tools. We have developed a fluorescence lifetime-based assay using an existing site-directed probe, N,N′-dimethyl-N-(iodoacetyl)-N′-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine (IANBD) attached to human cardiac troponin C (cTnC) mutant cTnCT53C, exchanged into porcine cardiac myofibrils. We hypothesized that IANBD-cTnCT53C fluorescence lifetime measurements provide insight into the activation state of the thin filament. The sensitivity and precision of detecting structural changes in cTnC due to physiological and therapeutic modulators of thick and thin filament functions were determined. The effects of Ca2+ binding to cTnC and myosin binding to the thin filament were readily detected by this assay in mock high-throughput screen tests using a fluorescence lifetime plate reader. We then evaluated known effectors of altered cTnC-Ca2+ binding, W7 and pimobendan, and myosin-binding drugs, mavacamten and omecamtiv mecarbil, used to treat cardiac diseases. Screening assays were determined to be of high quality as indicated by the Z′ factor. We conclude that cTnC lifetime-based probes allow for precise evaluation of the thin filament activation in functioning myofibrils that can be used in future high-throughput screens of small-molecule modulators of function of the thin and thick filaments.


  • Open Access

    Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity

    by Xiao Ma, Ping Zhu, Yonghe Ding, Hong Zhang, Qi Qiu, Alexey V. Dvornikov, Zheng Wang, Maengjo Kim, Yong Wang, Matthew Lowerison, et al.

    RXRA is an endothelial- and early stage–predominant therapeutic target for treating anthracycline-induced cardiotoxicity.


  • Open Access

    Haploinsufficiency of mechanistic target of rapamycin ameliorates bag3 cardiomyopathy in adult zebrafish

    by Yonghe Ding, Alexey V. Dvornikov, Xiao Ma, Hong Zhang, Yong Wang, Matthew Lowerison, Rene R. Packard, Lei Wang, Jun Chen, Yuji Zhang, et al.

    The adult zebrafish is an emerging vertebrate model for studying human cardiomyopathies; however, whether the simple zebrafish heart can model different subtypes of cardiomyopathies, such as dilated cardiomyopathy (DCM), remains elusive. Here, we generated and characterized an inherited DCM model in adult zebrafish and use this model to search for therapeutic strategies. We employed transcription activator-like effector nuclease (TALEN) genome editing technology to generate frame-shift mutants for the zebrafish ortholog of human Bcl2-associated athanogene 3 (BAG3), an established DCM-causative gene. As in mammals, the zebrafish bag3 homozygous mutant (bag3e2/e2) exhibited aberrant proteostasis, as indicated by impaired autophagy flux and elevated ubiquitinated protein aggregation. Through comprehensive phenotyping analysis of the mutant, we identified phenotypic traits that resembled DCM phenotypes in mammals, including cardiac chamber enlargement, reduced ejection fraction (EF) characterized by increased end-systolic volume/body weight (ESV/BW), and reduced contractile myofibril activation kinetics. Nonbiased transcriptome analysis identified the hyperactivation of the mechanistic target of rapamycin (mTOR) signaling in bag3e2/e2 mutant hearts. Further genetic studies showed that mtorxu015/+, an mTOR haploinsufficiency mutant, repaired abnormal proteostasis, improved cardiac function, and rescued the survival of the bag3e2/e2 mutant. This study established the bag3e2/e2 mutant as a DCM model in adult zebrafish and suggested mTOR as a candidate therapeutic target gene for BAG3 cardiomyopathy.


  • Open Access

    Retinoid X receptor alpha is a spatiotemporally-specific therapeutic target for doxorubicin-induced cardiomyopathy in adult zebrafish

    by Xiao Ma, Yonghe Ding, Hong Zhang, Qi Qiu, Alexey V. Dvornikov, Maengjo Kim, Yong Wang, Matthew Lowerison, Joerg Herrmann, Stephen C. Ekker, et al.

    While the genetic suppressor screen is efficient in suggesting therapeutic genes, this strategy has yet to be successful for cardiomyopathies in vertebrates. To develop such a strategy, we recently established a mutagenesis screen platform in zebrafish for systematic discovery of genetic modifiers of doxorubicin-induced cardiomyopathy (DIC). Here, we further revealed both molecular and cellular insights of the first salutary modifier emerged from the screen, i.e. gene-breaking transposon ( GBT ) 0419 that affects the retinoid X receptor alpha a ( rxraa ) gene. First, by rescuing the mutation in tissue-specific manner with multiple Cre-loxP systems, we demonstrated that the endothelial, but not myocardial or epicardial, function of rxraa is primary to this cardioprotective effects. Next, we showed that the rxraa -associated salutary effects on DIC were conferred partially by the activation of retinoid acid (RA) signaling. Finally, we identified isotretinoin and bexarotene, 2 US Food and Drug Administration-approved RXRA agonists that are effective in treating adult zebrafish DIC when administered during the early, but not the late, phase of DIC progression. Collectively, we provided the first in vivo genetic evidence in supporting RXRA as the therapeutic target for DIC, and uncovered a previously unrecognized spatiotemporally-restricted mechanism for this gene-based therapeutic strategy. Our study also justified that searching salutary modifiers via zebrafish mutagenesis screen can be effective in discovering new therapeutic targets for cardiomyopathies.

  • Phenotyping cardiomyopathy in adult zebrafish

    by Alexey V. Dvornikov, Pieter P. de Tombe, Xiaolei Xu


  • Open Access

    Robust activation of microhomology-mediated end joining for precision gene editing applications

    by Hirotaka Ata, Thomas L Ekstrom, Gabriel Martínez-Gálvez, Carla M Mann, Alexey V Dvornikov, Kyle J Schaefbauer, Alvin C Ma, Drena Dobbs, Karl J Clark, Stephen C Ekker

    One key problem in precision genome editing is the unpredictable plurality of sequence outcomes at the site of targeted DNA double stranded breaks (DSBs). This is due to the typical activation of the versatile Non-homologous End Joining (NHEJ) pathway. Such unpredictability limits the utility of somatic gene editing for applications including gene therapy and functional genomics. For germline editing work, the accurate reproduction of the identical alleles using NHEJ is a labor intensive process. In this study, we propose Microhomology-mediated End Joining (MMEJ) as a viable solution for improving somatic sequence homogeneity in vivo, capable of generating a single predictable allele at high rates (56% ~ 86% of the entire mutant allele pool). Using a combined dataset from zebrafish (Danio rerio) in vivo and human HeLa cell in vitro, we identified specific contextual sequence determinants surrounding genomic DSBs for robust MMEJ pathway activation. We then applied our observation to prospectively design MMEJ-inducing sgRNAs against a variety of proof-of-principle genes and demonstrated high levels of mutant allele homogeneity. MMEJ-based DNA repair at these target loci successfully generated F0 mutant zebrafish embryos and larvae that faithfully recapitulated previously reported, recessive, loss-of-function phenotypes. We also tested the generalizability of our approach in cultured human cells. Finally, we provide a novel algorithm, MENTHU (http://genesculpt.org/menthu/), for improved and facile prediction of candidate MMEJ loci. We believe that this MMEJ-centric approach will have a broader impact on genome engineering and its applications. For example, whereas somatic mosaicism hinders efficient recreation of knockout mutant allele at base pair resolution via the standard NHEJ-based approach, we demonstrate that F0 founders transmitted the identical MMEJ allele of interest at high rates. Most importantly, the ability to directly dictate the reading frame of an endogenous target will have important implications for gene therapy applications in human genetic diseases. New gene editing tools precisely break DNA at pre-defined genomic locations, but cells repair these lesions using diverse pathways that often lead to unpredictable outcomes in the resulting DNA sequences. This sequence diversity in gene editing outcomes represents an important obstacle to the application of this technology for human therapies. Using a vertebrate animal as a model system, we provide strong evidence that we can overcome this obstacle by selectively directing DNA repair of double-stranded breaks through a lesser-described pathway termed Microhomology-mediated End Joining (MMEJ). Unlike other, better-understood pathways, MMEJ uses recurring short sequence patterns surrounding the site of DNA breakage. This enables the prediction of repair outcomes with improved accuracy. Importantly, we also show that preferential activation of MMEJ is compatible with effective gene editing. Finally, we provide a simple algorithm and software for designing DNA-breaking reagents that have high chance of activating the MMEJ pathway. We believe that the MMEJ-centric approach to be broadly applicable for a variety of gene editing applications both within the laboratory and for human therapies.


  • Open Access

    A Langendorff-like system to quantify cardiac pump function in adult zebrafish

    by Hong Zhang, Alexey V. Dvornikov, Inken G. Huttner, Xiao Ma, Celine F. Santiago, Diane Fatkin, Xiaolei Xu

    Zebrafish are increasingly used as a vertebrate model to study human cardiovascular disorders. Although heart structure and function are readily visualized in zebrafish embryos because of their optical transparency, the lack of effective tools for evaluating the hearts of older, nontransparent fish has been a major limiting factor. The recent development of high-frequency echocardiography has been an important advance for in vivo cardiac assessment, but it necessitates anesthesia and has limited ability to study acute interventions. We report the development of an alternative experimental ex vivo technique for quantifying heart size and function that resembles the Langendorff heart preparations that have been widely used in mammalian models. Dissected adult zebrafish hearts were perfused with a calcium-containing buffer, and a beat frequency was maintained with electrical stimulation. The impact of pacing frequency, flow rate and perfusate calcium concentration on ventricular performance (including end-diastolic and end-systolic volumes, ejection fraction, radial strain, and maximal velocities of shortening and relaxation) were evaluated and optimal conditions defined. We determined the effects of age on heart function in wild-type male and female zebrafish, and successfully detected hypercontractile and hypocontractile responses after adrenergic stimulation or doxorubicin treatment, respectively. Good correlations were found between indices of cardiac contractility obtained with high-frequency echocardiography and with the ex vivo technique in a subset of fish studied with both methods. The ex vivo beating heart preparation is a valuable addition to the cardiac function tool kit that will expand the use of adult zebrafish for cardiovascular research.


  • Open Access

    Toward Precision Molecular Surgery: Robust, Selective Induction of Microhomology-mediated End Joining in vivo

    by Hirotaka Ata, Thomas L. Ekstrom, Gabriel Martínez-Gálvez, Carla M. Mann, Alexey V. Dvornikov, Kyle J. Schaefbauer, Alvin C. Ma, Drena Dobbs, Karl J. Clark, Stephen C. Ekker

    One key problem in precision genome editing is the resultant unpredictable plurality of sequence outcomes at the site of targeted DNA double-strand breaks (DSBs). This is due to the typical activation of the versatile Non-homologous End Joining (NHEJ) pathway. Such unpredictability limits the utility of somatic gene editing for applications including gene therapy and functional genomics. For germline editing work, the accurate reproduction of identical alleles using NHEJ is a labor intensive process. In this study, we propose inducing Microhomology-mediated End Joining (MMEJ) as a viable solution for improving somatic sequence homogeneity in vivo , capable of generating a single predictable allele at high rates (56% ~ 86% of the entire mutant allele pool). Using a combined dataset from zebrafish ( Danio rerio ) in vivo and human HeLa cell in vitro as a training dataset, we identified specific contextual sequence determinants surrounding genomic DSBs for robust MMEJ pathway activation. We then applied our observation and prospectively designed MMEJ-inducing sgRNAs against a variety of proof-of-principle genes and demonstrated a high level of mutant allele homogeneity at these loci. F0 mutant zebrafish embryos and larvae generated with these gRNAs faithfully recapitulated previously reported, recessive loss-of-function phenotypes. We also provide a novel algorithm MENTHU ( http://genesculpt.org/menthu/ ) for improved prediction of candidate MMEJ loci, suitable for both targeted and genome-wide applications. We believe that this MMEJ-centric approach will have a broad impact on genome engineering and its applications. For example, whereas somatic mosaicism hinders efficient recreation of a knockout mutant allele at base pair resolution via the standard NHEJ-based approach, we demonstrate that F0 founders transmitted the identical MMEJ allele of interest at high rates. Most importantly, the ability to directly dictate the reading frame of an endogenous target will have important implications for gene therapy applications in human genetic diseases. Author Summary: New gene editing tools precisely break DNA at pre-defined genomic locations, but cells repair these lesions using diverse pathways that often lead to unpredictable outcomes in the resulting DNA sequences. This sequence diversity in gene editing outcomes represents an important obstacle to the application of this technology for human therapies. Using a vertebrate animal as a model system, we provide strong evidence that we can overcome this obstacle by selectively directing DNA repair of double-stranded breaks through a lesser-described pathway termed Microhomology-mediated End Joining (MMEJ). Unlike other, better-understood pathways, MMEJ uses recurring short sequence patterns surrounding the site of DNA breakage. This enables the prediction of repair outcomes with improved accuracy. Importantly, we also show that preferential activation of MMEJ is compatible with effective gene editing. Finally, we provide a simple algorithm and software for designing DNA-breaking reagents that have high chance of activating the MMEJ pathway. We believe that the MMEJ-centric approach to be broadly applicable for a variety of gene editing applications both within the laboratory and for human therapies. Author Contribution: HA contributed in Conceptualization, Data Curation, Formal Analysis, Investigation, Funding Acquisition, Methodology, Validation, Visualization, Writing – Original draft preparation, and Writing – Review and Editing. TLE contributed in Data Curation, Investigation, Writing – Original draft preparation, and Writing – Review and Editing. GMG contributed in Software, Validation, and Writing. CMM contributed in Software Validation, and Writing. AVD contributed in Investigation, Methodology, Validation, and Writing – Review and Editing. KJS contributed in Investigation and Writing – Review and Editing. ACM contributed in Conceptualization, Data Curation, Investigation, and Writing – Review and Editing. DD contributed in Funding Acquisition, Resources, and Writing – Review and Editing. KJC contributed in Conceptualization, Funding Acquisition, Resources, Supervision, and Writing – Review and Editing. SCE contributed in Conceptualization, Funding Acquisition, Project Administration, Resources, Supervision, Writing – Review and Editing.


  • Open Access

    Pacing Therapy and Quality of Life in Sick Sinus Syndrome Patients

    by A. Ardashev, A. Dzhandzhgava, A. Dvornikov

    To compare quality of life (QoL) parameters in sick sinus syndrome patients after implantation of VVI-, AAI- and DDD-pacemakers during long-term follow-up. The study group consisted of 143 patients (20 women), 69.8±11.1 years of age, in whom permanent pacemaker had been implanted between January, 1996 and December, 2002. Follow-up duration was 61.1±23.9 months. Patients were subdivided into 3 subgroups. Subgroup A: 75 patients with VVI-pacemaker; subgroup B: 38 patients with AAI-pacemaker; subgroup C: 30 patients with DDD pacemaker. Short Form (MOS-SF-36) was used to assess QoL measurements. Sick sinus syndrome patients who received AAI- and DDD-pacemakers had higher mental and physical component summary scores compared with patients who received VVI-therapy. QoL measurements did not differ significantly between subgroup B and the subgroup C patients. DDD-therapy was followed by improved performance of social activity in majority of patients. VVI-pacing was associated with worsening in emotional role functioning. The AAI- and DDD-therapy was associated with higher QoL parameters in sick sinus syndrome patients compared with VVI-patients during long-term follow-up.